Study guide

8.3 Anesthetics, Glaucoma Agents & Prescription Verification

IJCAHPO Certified Retina Technician CRT

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview: Current CRT Requirements & Blueprint

Exam Overview: Current Requirements, Scope & Study Plan

2 Chapter 1: History Taking, Triage & Clinical Documentation

1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes

3 Chapter 2: Visual Assessment & Low Vision Rehabilitation

2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling

4 Chapter 3: Pupil Assessment & Visual Field Testing

3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring

5 Chapter 4: Tonometry & Ocular Motility

4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing

6 Chapter 5: Diagnostic Ophthalmic Ultrasound

5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry

7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing

6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG

8 Chapter 7: Ophthalmic Microbiology & Infection Control

7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection

9 Chapter 8: General Retinal Pharmacology & Therapeutics

8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification

10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity

9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

11 Chapter 10: Surgical Assisting & Intravitreal Procedures

10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization

12 Chapter 11: Patient Services, Education & Clinical Care

11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals

13 Chapter 12: General Ocular Anatomy & Retinal Physiology

12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology

14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations

13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments

15 Chapter 14: Ophthalmic Optics & Lensometry

14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques

16 Chapter 15: Fundus Photography & Ophthalmic Angiography

15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management

17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)

16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow

18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance

17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal

8.3 Anesthetics, Glaucoma Agents & Prescription Verification

Key Takeaways Explain This Topic AI

Topical ocular anesthetics block sodium channels and can provide rapid surface anesthesia; onset, duration, concentration, and permitted use depend on the specific product and authorized order.

Repeated unsupervised topical-anesthetic use can cause severe corneal toxicity; a technician must not prescribe, dispense, or recommend take-home use independently.

Glaucoma drugs have ocular and systemic precautions; capture pulmonary, cardiac, renal, allergy, lens, and inflammation history and route it to the prescriber rather than declaring a contraindication independently.

Cap-color conventions are secondary cues, not medication identity; always verify the written label, drug, concentration, patient, route, expiration, and order.

Medication storage is product-specific. Monitor the labeled temperature and light conditions, quarantine excursions, and obtain an authorized pharmacy or manufacturer disposition.

Last updated: September 2026

Anesthetics, Glaucoma Medicines, and Prescription Verification

Medication support begins with two identifiers and a complete comparison of patient, eye, drug, concentration, dosage form, route, directions, allergies or prior reactions, expiration, label, and authorized order. Stop for a mismatch, unclear abbreviation, damaged seal, particles, discoloration outside the label description, missing storage history, or an unexplained change.

Topical anesthetics

Proparacaine, tetracaine, and other topical ocular anesthetics block nerve conduction at the ocular surface. They may be ordered for tonometry, contact-lens examination, minor procedures, or diagnostic manipulation. Product concentration, onset, duration, storage, and number of instillations differ.

Repeated unsupervised use can suppress epithelial healing and protective sensation, producing persistent defects, infection, stromal injury, or perforation. A technician must not independently prescribe, dispense, or recommend a clinic bottle for home use. A patient's request for pain medicine or repeated anesthetic is routed to the licensed clinician for diagnosis, safer analgesia, and follow-up.

Glaucoma medication classes

Prostaglandin analogs increase uveoscleral outflow. Record inflammation, lens status, macular-edema history, pregnancy considerations, iris or eyelash changes, and the exact product; the prescriber weighs relevance.

Beta blockers reduce aqueous production but can worsen bronchospasm, bradycardia, conduction disease, or heart failure through systemic absorption. Capture asthma, COPD, pulse, cardiac history, and interacting systemic drugs.

Alpha-2 agonists reduce aqueous production and can cause allergy, fatigue, dry mouth, hypotension, or central nervous system effects. Pediatric age and product labeling require special attention.

Carbonic anhydrase inhibitors may be topical or systemic. Record renal disease, electrolyte problems, prior reaction details, and interacting therapy. Do not reduce every sulfonamide history to an automatic conclusion; the prescriber evaluates the actual reaction and product.

Cholinergic agents can cause miosis, brow ache, accommodative symptoms, and retinal or systemic concerns in selected patients. Verify the indication and report new flashes, floaters, field loss, or severe symptoms.

Combination products contain more than one active ingredient. Medication reconciliation must capture the generic components so therapy is not duplicated under different brand names.

Cap color and label reading

Ophthalmic cap-color conventions can support communication, but generics, combination products, packaging, and accessibility needs vary. Never identify a bottle by color alone. Read the full label at retrieval, preparation, and administration. For a patient with low vision, use accessible labeling and teach-back rather than asking the person to rely solely on cap color.

Instilling drops and ointment

Perform hand hygiene, explain the task, verify the eye, inspect the tip, and position the patient safely. With the patient looking up, gently lower the lid to expose the conjunctival sac without touching the globe. Instill the ordered amount without contacting lashes, skin, or ocular surface. Ask the patient to close the lids gently; use punctal occlusion only when ordered or instructed for that medication and patient. Do not squeeze the lids or press on a recently operated or injured eye.

For ointment, place the ordered thin ribbon in the lower conjunctival sac without tip contact, then warn about temporary blur. Mixing of a suspension, sequence of multiple drugs, interval between products, and contact-lens removal follow the label and order. A contaminated tip or shared single-patient product is handled under policy rather than wiped and returned automatically.

Document drug, concentration, eye, time, dose or drops, relevant checks, tolerance, and any refusal or omission. Escalate unexpected pain, breathing difficulty, faintness, marked pulse change, facial swelling, or acute vision symptoms.

Prescription and inventory controls

A valid prescription or medication order identifies the patient, date, drug, strength, dosage form, route and eye, directions, quantity or duration as applicable, refills, and authorized prescriber under current law and policy. Never invent a missing laterality or convert an ophthalmic product to an otic or oral formulation.

Separate look-alike and sound-alike products, retain lot and expiration traceability where required, rotate stock by expiration, and monitor the labeled temperature and light conditions. Quarantine an excursion, broken package, suspected counterfeit, recall, or uncertain beyond-use time. Appearance alone cannot establish potency or sterility.

Additional medication classes in the CRT blueprint

The technician recognizes why a class may be ordered, screens the relevant history, and observes for adverse effects without independently selecting therapy.

Class Typical ophthalmic purpose Safety and documentation focus

Anti-infectives Antibacterial, antiviral, antifungal, or antiparasitic treatment selected for the suspected or proven organism Verify organism or indication when documented, route, allergy reaction, renal or hepatic issues when relevant, interactions, and exact ordered duration; these classes are not interchangeable

Allergy medicines Topical antihistamine, mast-cell stabilizing, or combination relief for allergic conjunctival symptoms Distinguish allergy symptoms from pain, photophobia, corneal involvement, purulent discharge, or vision loss that needs clinician review; avoid recommending chronic vasoconstrictor use independently

Corticosteroids Suppression of ocular inflammation and selected retinal edema, including implants or injections Infection can worsen or be masked; pressure elevation, cataract, delayed healing, and procedure risks require ordered monitoring and tapering only by the prescriber

Nonsteroidal anti-inflammatory drugs Selected pain or inflammation control and perioperative use Corneal toxicity, delayed healing, allergy, renal or bleeding considerations, and product-specific warnings matter; do not assume an oral and topical drug have the same risk profile

Ocular lubricants Tear-film supplementation and surface comfort Preservatives, contact-lens compatibility, contamination, viscosity, blur, and frequency affect product choice; pain or reduced vision is not treated as routine dryness without review

Systemic immunomodulators and retinal-risk drugs Drugs such as adalimumab may control inflammatory disease, while hydroxychloroquine, tamoxifen, pentosan polysulfate, and other agents have ocular monitoring implications Record exact generic name, dose, route, start date, indication, prescriber, immune or infection history, and ordered screening; never tell the patient to stop a systemic medicine independently

For drops and ointments, verify the label and order, wash hands, avoid touching the tip, instill into the conjunctival sac as directed, and document eye, agent, concentration, and time. Ointment is placed as a thin ribbon according to the order and can blur vision. If more than one product is ordered, separation and sequence come from the prescription, label, pharmacy, or facility protocol rather than a memorized universal interval.